These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 17129175)

  • 1. Immunobiology of allogeneic hematopoietic stem cell transplantation.
    Welniak LA; Blazar BR; Murphy WJ
    Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
    Har-Noy M; Slavin S
    Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
    D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
    Front Immunol; 2020; 11():989. PubMed ID: 32528476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
    Espinoza-Delgado I; Childs RW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
    Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
    Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hematopoietic stem cell transplantation: is it an immunologic therapy?].
    Olaya Vargas A; Pérez Gonzáles O
    Rev Alerg Mex; 2003; 50(5):192-7. PubMed ID: 14631591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
    Bouchlaka MN; Redelman D; Murphy WJ
    Immunotherapy; 2010 May; 2(3):399-418. PubMed ID: 20635904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematopoietic cell transplantation as immunotherapy.
    Appelbaum FR
    Nature; 2001 May; 411(6835):385-9. PubMed ID: 11357147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
    Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
    J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will post-transplantation cell therapies for pediatric patients become standard of care?
    Lankester AC; Locatelli F; Bader P; Rettinger E; Egeler M; Katewa S; Pulsipher MA; Nierkens S; Schultz K; Handgretinger R; Grupp SA; Boelens JJ; Bollard CM;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):402-11. PubMed ID: 25064748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic haematopoietic stem cell transplantation - an overview].
    Holtick U; Chemnitz JM; Hallek M; Scheid C
    Klin Monbl Augenheilkd; 2015 May; 232(5):641-6. PubMed ID: 25989032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.
    Tsirigotis P; Or R; Resnick IB; Shapira MY
    Immunotherapy; 2012 Apr; 4(4):407-24. PubMed ID: 22512635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.